Comment to "Antithrombin III administration for portal vein thrombosis in patients with liver disease
Blasi, Annabel; Saner, Fuat; Biancofiore, Gianni; Lisman, Ton

Published in:
Hepatology Research

DOI:
10.1111/hepr.12987

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 05-08-2020
Letter to the Editor

Comment to “Antithrombin III administration for portal vein thrombosis in patients with liver disease: A randomized double-blind controlled trial”

Dear Editor,

We read with great interest the paper by Hidaka and colleagues who randomized patients with mild to moderate cirrhosis (Child–Pugh score < 11) with a recently diagnosed portal vein thrombosis (PVT) and an antithrombin (AT) plasma level < 70% between treatment with placebo or AT concentrate for a maximum of 15 days.1 Although thrombus resolution in the short term was substantially improved in the AT arm, we think that the authors’ conclusion that AT “should be considered an essential therapy for PVT in patients with liver disease” is premature.

Previous studies showed that thrombus resolution requires prolonged anticoagulant therapy (5–7 months).2,3 Also, in patients who showed no recanalization after 6 months of anticoagulant therapy, total portal vein recanalization was reported after another 6 months of therapy.4 Notably, spontaneous recanalization of PVT is reported in up to 40% of cases.8–10 Based on these data, the rationale for giving a short course of AT supplementation is unclear. Hidaka et al.’s data actually suggest AT concentrate to lead to almost instantaneous thrombolysis, which is a mechanism that in our opinion lacks biological plausibility.

Patients with compensated cirrhosis are in a fragile hemostatic balance due to a concomitant decline in pro- and anticoagulant factors.5 This fragile balance will be disrupted by administration of AT concentrate, which likely increases bleeding risk. We therefore disagree with the authors’ statement that selective supplementation of AT is not associated with a bleeding risk.

As cirrhosis is a chronic condition, the risk of recurrent PVT after successful recanalization with a short-term course of AT concentrate may be high.

Nowadays, despite the lack of consensus on the type of anticoagulant, dose, and treatment duration, the majority of patients with PVT are given anticoagulants.6,7 We feel Hidaka’s study should have included a comparator arm of a conventional anticoagulant to better appreciate mechanisms underlying the rapid effect of AT concentrate. Based on literature, conventional anticoagulants are likely to decrease coagulation activation and increase fibrin breakdown, but are not expected to result in thrombus resolution in just 5–15 days.

As the risk of PVT increases with the severity of the cirrhosis,8 Hidaka’s study, with Child–Pugh < 11 patients only, did not study the vast majority of cirrhotic PVT patients. Notably, Hidaka’s study included 104 patients from 55 hospitals over a period of 1.5 years, which indicates the group is likely highly selected.

If short-term AT supplementation really is as beneficial as it appears from Hidaka’s data, AT concentrate might also benefit PVT patients with AT > 70%.

Finally, we would like to outline that, at present, it is still unclear whether treatment of PVT is (always) indicated because several factors need to be considered, namely, site of the thrombus, severity of the liver disease, comorbidities, and whether the patients is a liver transplant candidate.6

In aggregate, further studies with a less selected patient population, longer follow-up, and additional studies on mechanism of action are required before AT concentrate can be considered essential in the management of PVT.

Annabel Blasi1, Fuat Sane2, Gianni Biancofiore3 and Ton Lisman4

1Anesthesiology Department, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain, 2Department of General, Visceral and Transplantation Surgery, Essen University Medical Center, Essen, Germany, 3Transplant Anesthesia and Critical Care, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy and 4Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

REFERENCES


© 2017 The Japan Society of Hepatology


